Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 112 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumours... October 29, 2020 Newly Developed International Childhood Cancer Core Outcome Set Represents Physical, Psychosocial,... July 11, 2023 First New Drug in Years Reduces Recurrence in High-risk Hormone Receptor... September 20, 2020 EMA Recommends Extension of Indications for Trastuzumab Deruxtecan to Include Treatment... March 21, 2025 Load more HOT NEWS How to Talk About Advanced Cancer Care Planning: An Expert Discussion ΝΕΑ ΓΙΑ ΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ Our nurses answer your frequently asked questions about cancer Neoadjuvant Histotype-Tailored Treatment with Trabectedin Not Inferior to Standard Chemotherapy with...
